Lunai Bioworks R&D Spending Growth & History (LNAI)
Lunai Bioworks's r&d spending was $537,428 for fiscal 2025.
View full Lunai Bioworks company overviewLunai Bioworks annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $537,428 | −$2.2M | −80.16% |
| 2024 | 2024-06-30 | $2.7M | −$1.5M | −34.97% |
| 2023 | 2023-06-30 | $4.2M | −$4.2M | −50.25% |
| 2022 | 2022-06-30 | $8.4M | −$7.3M | −46.74% |
| 2021 | 2021-06-30 | $15.7M | $11.0M | +234.88% |
| 2020 | 2020-06-30 | $4.7M | $2.2M | +87.92% |
| 2019 | 2019-06-30 | $2.5M | $1.9M | +304.91% |
| 2018 | 2018-06-30 | $616,961 | $554,198 | +883.00% |
| 2017 | 2017-06-30 | $62,763 | −$741,425 | −92.20% |
| 2016 | 2016-06-30 | $804,188 | −$821,300 | −50.53% |
| 2015 | 2015-06-30 | $1.6M | — | — |
Lunai Bioworks quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $15,946 | −$78,127 | −83.05% |
| Q2 2026 | 2025-12-31 | $45,872 | −$115,212 | −71.52% |
| Q1 2026 | 2025-09-30 | $24,407 | −$365,782 | −93.74% |
| Q4 2025 | 2025-06-30 | $80,228 | −$354,280 | −81.54% |
| Q3 2025 | 2025-03-31 | $94,073 | −$993,083 | −91.35% |
| Q2 2025 | 2024-12-31 | $161,084 | −$459,437 | −74.04% |
| Q1 2025 | 2024-09-30 | $390,189 | −$176,455 | −31.14% |
| Q4 2024 | 2024-06-30 | $434,508 | −$560,218 | −56.32% |
| Q3 2024 | 2024-03-31 | $1.1M | $848,019 | +354.62% |
| Q2 2024 | 2023-12-31 | $620,521 | $294,562 | +90.37% |
| Q1 2024 | 2023-09-30 | $566,644 | −$2.0M | −78.25% |
| Q4 2023 | 2023-06-30 | $994,726 | −$773,037 | −43.73% |
| Q3 2023 | 2023-03-31 | $239,137 | −$973,243 | −80.28% |
| Q2 2023 | 2022-12-31 | $325,959 | −$2.0M | −86.05% |
| Q1 2023 | 2022-09-30 | $2.6M | −$450,060 | −14.73% |
| Q4 2022 | 2022-06-30 | $1.8M | −$10.4M | −85.53% |
| Q3 2022 | 2022-03-31 | $1.2M | $93,177 | +8.33% |
| Q2 2022 | 2021-12-31 | $2.3M | $1.0M | +75.14% |
| Q1 2022 | 2021-09-30 | $3.1M | $2.0M | +190.89% |
| Q4 2021 | 2021-06-30 | $12.2M | $10.9M | +835.86% |
| Q3 2021 | 2021-03-31 | $1.1M | −$1.2M | −51.49% |
| Q2 2021 | 2020-12-31 | $1.3M | $773,000 | +137.67% |
| Q1 2021 | 2020-09-30 | $1.1M | $530,184 | +101.92% |
| Q4 2020 | 2020-06-30 | $1.3M | $820,024 | +168.96% |
| Q3 2020 | 2020-03-31 | $2.3M | $1.6M | +215.96% |
| Q2 2020 | 2019-12-31 | $561,468 | −$227,500 | −28.84% |
| Q1 2020 | 2019-09-30 | $520,192 | $26,637 | +5.40% |
| Q4 2019 | 2019-06-30 | $485,329 | $379,905 | +360.36% |
| Q3 2019 | 2019-03-31 | $730,255 | $592,339 | +429.49% |
| Q2 2019 | 2018-12-31 | $788,968 | $568,999 | +258.67% |
| Q1 2019 | 2018-09-30 | $493,555 | $339,903 | +221.22% |
| Q4 2018 | 2018-06-30 | $105,424 | $89,842 | +576.58% |
| Q3 2018 | 2018-03-31 | $137,916 | $121,626 | +746.63% |
| Q2 2018 | 2017-12-31 | $219,969 | $206,182 | +1495.48% |
| Q1 2018 | 2017-09-30 | $153,652 | $136,548 | +798.34% |
| Q4 2017 | 2017-06-30 | $15,582 | −$173,272 | −91.75% |
| Q3 2017 | 2017-03-31 | $16,290 | −$219,637 | −93.10% |
| Q2 2017 | 2016-12-31 | $13,787 | −$263,861 | −95.03% |
| Q1 2017 | 2016-09-30 | $17,104 | −$84,655 | −83.19% |
| Q4 2016 | 2016-06-30 | $188,854 | — | — |
| Q3 2016 | 2016-03-31 | $235,927 | $84,114 | +55.41% |
| Q2 2016 | 2015-12-31 | $277,648 | — | — |
| Q1 2016 | 2015-09-30 | $101,759 | −$41,390 | −28.91% |
| Q1 2015 | 2015-03-31 | $151,813 | — | — |
| Q3 2014 | 2014-09-30 | $143,149 | $143,149 | — |
| Q2 2013 | 2013-09-30 | $0 | — | — |
Lunai Bioworks r&d spending trends
Over the last five fiscal years, Lunai Bioworks's r&d spending decreased from $4.7M to $537,428, a change of −$4.2M. The latest reported quarter, Q3 2026, shows $15,946.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lunai Bioworks source filings ↗